Zealand Announces Advance by Sanofi of LixiLan, the Single Injection Lyxumia(R)/Lantus(R) Combination Product, Towards Phase III Development and a Related Milestone Payment

Zealand Pharma A/S (NASDAQ OMX Copenhagen:ZEAL) ("Zealand") announces that under its license agreement with Sanofi (EURONEXT:SAN) (NYSE: SNY ) covering Lyxumia(r) (lixisenatide) and any combination product including lixisenatide, a milestone has been achieved in the advance of LixiLan, the once-daily single injection Lantus(r) (basal insulin) / Lyxumia(r) (lixisenatide) combination